Labiotech.eu

News and Trends 23 Feb 2023

Depression trial gets green light

Beckley Psytech Ltd has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a global multi-site phase IIb study exploring the safety, efficacy and tolerability of two doses of its lead compound, BPL–003, in patients with treatment resistant depression (TRD). BPL-003 is the Beckley Psytech’s novel synthetic formulation of […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Positive topline data from sepsis trial

Modus Therapeutics AB has published positive top-line data from its phase 1b lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis and other conditions with systemic inflammation. In the study, healthy volunteers received LPS to induce a transient systemic inflammation reaction together with […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

New promising targeted drug for a rare leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option for the treatment of acute myeloid leukemia (AML). It was recently granted marketing authorization in Finland. Venetoclax works by sensitizing cancer cells to programmed cell […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Sherlock obtains Cas12 CRISPR patent

Sherlock Biosciences, a company engineering biology to bring next-generation lab-quality diagnostic testing to the point of need, has announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme. Sherlock Biosciences has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, plus additional intellectual […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Italian life sciences fund hits €175M

Panakès Partners, an Italian venture capital firm in the life sciences sector, has closed its Purple Fund with a total of €175 million ($185.4 million). Panakès Purple Fund is currently the largest Italian Venture Capital Fund, in the investment phase, dedicated to life sciences, with an investment focus in Italy and Europe, as well as […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Korean researchers develop antimicrobial peptides discovery tool

Antimicrobial peptides (AMPs) are a promising new weapon for combating the growing antimicrobial resistance (AMR) of bacteria and other harmful microorganisms. Now, researchers from the Gwangju Institute of Science and Technology (GIST) in South Korea have developed a new, easy-to-interpret AI-powered AMP prediction model. The tool, named AMP-BERT, can capture the functional and structural properties […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders

Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has announced the closing of an oversubscribed $135 million Series B financing. Access Biotechnology led the round, with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity, as well […]

February 21, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

HKUMed develops nanoparticle-based targeted drug delivery system

A research team from LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed thyroid hormone (TH) – encapsulated nanoparticles modified with adipose-homing peptide, which selectively transport TH to adipose tissues. The researchers say this will advance the treatment of obesity-related medical complications with TH by overcoming its severe adverse effects caused by […]

February 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

Can CRISPR correct type 2 diabetes gene?

Swedish researchers have identified 395 genes that are differently expressed in people with type 2 diabetes. One of these (PAX5) has proven to be very strongly associated with impaired insulin secretion. Now, researchers want to investigate if it is possible to use the genetic CRISPR/Cas9 scissors to correct the gene’s activity. The research team’s scientific […]

February 21, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

New event set to take place in Swedish biotech hub

A new event, which will include presentations by Nobel laureates, is set to showcase the best of pharmacology. The Lund Spring Symposium, which takes place from May 24 to 26 at the Palaestra et Odeum in Lund, Sweden, aims to raise the profile of pharmacology as a cross-functional discipline in the 21st Century and to […]

February 21, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 21 Feb 2023

First patient enrolled in Pharming APSD trial

Pharming Group N.V. says the first patient has been enrolled in its phase III clinical trial evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome (APDS). There is currently no approved treatment for this complex and progressive disease caused by genetic variants. At […]

February 21, 2023 - 6 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Depression trial gets green light

Positive topline data from sepsis trial

New promising targeted drug for a rare leukemia

Sherlock obtains Cas12 CRISPR patent

Italian life sciences fund hits €175M

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Korean researchers develop antimicrobial peptides discovery tool

Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders

HKUMed develops nanoparticle-based targeted drug delivery system

Can CRISPR correct type 2 diabetes gene?

New event set to take place in Swedish biotech hub

First patient enrolled in Pharming APSD trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!